Evidence map›Paper›PMID 26729203›Full record

ArticleMetabolic brain disease2016

Echinocystic acid reduces reserpine-induced pain/depression dyad in mice.

Shuo Li, Jing Han, Dong-Sheng Wang, Bin Feng, Ya-Ting Deng, Xin-Shang Wang, Qi Yang, Ming-Gao Zhao

Abstract read
PubMed Publisher
In one paragraph

Article in Metabolic brain disease, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.2field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 35 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Shuo LiDepartment of Pharmacology, School of Pharmacy, The Fourth Military Medical University, Xi'an, 710032, China.
Jing HanDepartment of Pharmacology, School of Pharmacy, The Fourth Military Medical University, Xi'an, 710032, China.
Dong-Sheng WangDepartment of Orthopedics, Jinling Hospital, Clinical School of Nanjing, Second Military Medical University, Nanjing, 210002, China.
Bin FengDepartment of Pharmacology, School of Pharmacy, The Fourth Military Medical University, Xi'an, 710032, China.
Ya-Ting DengDepartment of Pharmacology, School of Pharmacy, The Fourth Military Medical University, Xi'an, 710032, China.
Xin-Shang WangDepartment of Pharmacology, School of Pharmacy, The Fourth Military Medical University, Xi'an, 710032, China.
Qi YangDepartment of Pharmacology, School of Pharmacy, The Fourth Military Medical University, Xi'an, 710032, China.
Ming-Gao ZhaoDepartment of Pharmacology, School of Pharmacy, The Fourth Military Medical University, Xi'an, 710032, China. minggao@fmmu.edu.cn.
Air Force Medical University · CNSecond Military Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic pain has consistently been correlated with depression. Echinocystic acid (EA), a natural triterpone enriched in various herbs and used for medicinal purpose in many Asian countries, exhibits anti-inflammatory and analgesic activities. However, little is known the effects of EA on the depression. In present study, we investigated the anti-depression activities in the mouse model of reserpine-induced pain-depression dyad. Reserpine (1 mg/kg subcutaneously daily for 3 days) caused significant depression-like behaviors and pain sensation. Subsequent treatment of EA (5 mg/kg intragastrically daily for 5 days) attenuated the reserpine-induced pain/depression dyad as shown by the increase of pain threshold and the behaviors in forced swimming test, tail suspension test, and open field test. Furthermore, treatment of EA reversed the decrease of biogenic amines (norepinephrine, dopamine, and serotonin) in the brain region of hippocampus, a structure involved in the formation of emotional disorders. Levels of serotonin receptor 5-HT1A were decreased and levels of 5-HT2A were increased in the reserpine-injected mice. Treatment of EA could restore the alterations of serotonin receptors. At the same time, the increase in GluN2B-containing NMDA receptors, p-GluA1-Ser831, PSD-95 and CaMKII were integrated with the increase in caspase-3 and iNOS levels in the hippocampus of the reserpine-injected mice. EA significantly reversed the changes of above proteins. However, EA did not affect the levels of GluN2A-containing NMDA receptors and the total levels of GluA1 and p-GluA1-Ser845. Our study provides strong evidence that EA attenuates reserpine-induced pain/depression dyad partially through regulating the biogenic amines levels and GluN2B receptors in the hippocampus.

Indexed as

AnalgesicsAnimalsBehavior, AnimalBrainDepressionDepressive DisorderDisease Models, AnimalDopamineMaleMice, Inbred C57BLOleanolic AcidPainPain ThresholdReceptors, N-Methyl-D-AspartateReserpineSerotoninAnalgesicsDopamineechinocystic acidOleanolic AcidReceptors, N-Methyl-D-AspartateReserpineSerotoninDepressionEchinocystic acidHippocampusNMDA receptorPainSerotonin

Identifiers

PMID26729203
OpenAlexW2222366320

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.